* Absci Corp ABSI.OQ reported a quarterly adjusted loss
of 25
cents per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of -21
cents. The mean expectation of six analysts for the quarter was
for a loss of 25 cents per share. Wall Street expected
results to range from -27 cents to -21 cents per share.
* Revenue fell 78.3% to $338.00 thousand from a year ago;
analysts
expected $1.03 million.
* Absci Corp's reported EPS for the quarter was a loss of 25
cents.
* The company reported a quarterly loss of $23.55 million.
* Absci Corp shares had risen by 17.9% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 9.8%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Absci Corp is
$8.00
This summary was machine generated from LSEG data March 25 at
09:06 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.25 -0.25 Met
Sep. 30 2023 -0.23 -0.24 Missed
Jun. 30 2023 -0.24 -0.45 Missed
Mar. 31 2023 -0.24 -0.26 Missed